Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics, Inc. is trading at $26.53, up 5.87% on the session. The 50 day average sits at $41.06 and the 200 day at $35.76, which puts the stock in a uptrend. RSI is at 24.4, which reads as oversold, and MACD is bearish crossover. Volume is below average.

The nearest support is around $26.93 with resistance near $34.48, so that band frames the current range. Average daily movement is roughly $2.08, or about 7.8% of the share price, which is what any stop placement has to allow for. The overall health score of 30 out of 100 combines a trend score of 30, momentum of 28 and a risk score of 34.

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.